<DOC>
	<DOCNO>NCT01784107</DOCNO>
	<brief_summary>Phase 1 : To evaluate MTD ( Maximal tolerate dose ) DLT ( Dose limit Toxicity ) Belotecan Ifosfamide . Phase 2 : To analyse efficacy toxicity Belotecan Ifosfamide .</brief_summary>
	<brief_title>A Phase Ib/II Trial Belotecan Ifosfamide Patients With Extensive Disease Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Belotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>histologically cytologically confirm extensive disease Small cell lung cancer prior chemotherapy radiotherapy lung measurable lesion RECIST 18 year ECOG 0~2 expected life span 3 month acute active infection uncontrolled cerebral nerve symptom metastasis significant myocardial infarction cardiac disease within 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>SCLC</keyword>
	<keyword>belotecan</keyword>
	<keyword>Ifosfamide</keyword>
</DOC>